- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 20.08. | Spago Nanomedical Interim Report January-June, 2025 | 239 | ACCESS Newswire | LUND, SE / ACCESS Newswire / August 20, 2025 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F)APRIL - JUNE IN BRIEFNet sales for the quarter amounted to KSEK 81 (KSEK 459)The loss for the quarter amounted... ► Artikel lesen | |
| SPAGO NANOMEDICAL Aktie jetzt für 0€ handeln | |||||
| 03.06. | Spago Nanomedical Continues Patient Recruitment in the Phase I/IIa Study Tumorad-01 as Planned after DMC Recommendation | 255 | ACCESS Newswire | LUND, SE / ACCESS Newswire / June 3, 2025 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) - Spago Nanomedical AB (publ) announced today that the Data Monitoring Committee (DMC) recommends the ongoing... ► Artikel lesen | |
| 14.05. | Bulletin from the 2025 Annual General Meeting of Spago Nanomedical AB | 285 | ACCESS Newswire | LUND, SE / ACCESS Newswire / May 14, 2025 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) - The Annual General Meeting (AGM) of Spago Nanomedical AB (publ) was held today, May 14, 2025, at which the AGM... ► Artikel lesen | |
| 07.05. | Spago Nanomedical Interim Report January-March, 2025 | 310 | ACCESS Newswire | LUND, SE / ACCESS Newswire / May 7, 2025 / Spago Nanomedical (STO:SPAGO.ST) (FRA:7UX.F)OCTOBER - DECEMBER IN BRIEFNet sales for the quarter amounted to KSEK 338 (KSEK 350)The loss for the quarter amounted... ► Artikel lesen | |
| 15.04. | Spago Nanomedical Publishes The Annual Report for 2024 | 318 | ACCESS Newswire | LUND, SE / ACCESS Newswire / April 15, 2025 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F)Spago Nanomedical's annual report for 2024 is from today available at the company's website, https://spagonanomedical.se/investor-relations/financial-reportsFor... ► Artikel lesen | |
| 09.04. | Notice To Annual General Meeting of Spago Nanomedical AB | 330 | ACCESS Newswire | LUND, SE / ACCESS Newswire / April 9, 2025 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F)This English version of the notice to the Annual General Meeting is for convenience only. The Swedish version... ► Artikel lesen | |
| 20.03. | Nomination Committee's Proposal for a New Chairman and Composition of Spago Nanomedical's Board | 640 | ACCESS Newswire | LUND, SE / ACCESS Newswire / March 20, 2025 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) announced today that the company's nomination committee proposes a changed board... ► Artikel lesen | |
| 04.03. | Spago Nanomedical Proceeds with Increased Dose in the Phase I/IIa study Tumorad-01 | 355 | ACCESS Newswire | LUND, SE / ACCESSWIRE / March 04, 2025 / Spago Nanomedical (STO:SPAGO.ST) (FRA:7UX.F) Spago Nanomedical AB (publ) announced today that the independent Data Monitoring Committee (DMC) recommends a dose... ► Artikel lesen | |
| 06.02. | Spago Nanomedical year-end report January-December, 2024 | 277 | ACCESS Newswire | LUND, SE / ACCESS Newswire / February 6, 2025 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F)OCTOBER - DECEMBER IN BRIEFNet sales for the quarter amounted to KSEK 617 (KSEK 731)The loss for the quarter... ► Artikel lesen | |
| 15.01. | Spago Nanomedical Article on SPAGOPIX-01 Clinical Results Accepted for Publication in Investigative Radiology | 254 | ACCESS Newswire | LUND, SWEDEN / ACCESSWIRE / January 15, 2025 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) announced today that a manuscript on product candidate pegfosimer manganese has... ► Artikel lesen | |
| 18.12.24 | Second Patient Group Successfully Dosed in Spago Nanomedical's Phase I/IIa Study Tumorad-01 | 450 | ACCESS Newswire | LUND, SE / ACCESSWIRE / December 18, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) today announced that all patients in the second patient group have been dosed according... ► Artikel lesen | |
| 06.11.24 | Spago Nanomedical Interim Report January-September 2024 | 293 | ACCESS Newswire | LUND, SWEDEN / ACCESSWIRE / November 6, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Progress for the Tumorad programJULY - SEPTEMBER IN BRIEFNet sales for the quarter amounted to KSEK 485 (KSEK... ► Artikel lesen | |
| 21.10.24 | Nomination Committee Appointed for Spago Nanomedical's Annual General Meeting 2025 | 287 | ACCESS Newswire | LUND, SE / ACCESSWIRE / October 21, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) In accordance with the instructions to the nomination committee resolved by the Annual General Meeting ("AGM")... ► Artikel lesen |
13 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ADMA BIOLOGICS | 14,660 | +0,89 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| QIAGEN | 39,740 | +0,68 % | Kaum Impulse für die Qiagen NV-Aktie (37,58 €) | Wenig Kursbewegung zur Stunde bei dem Anteilsschein von Qiagen NV . Der jüngste Kurs betrug 37,58 Euro. Einen minimalen Wertanstieg von 0,17 Prozent zeigt die Kurstafel für der Anteilsschein von Qiagen... ► Artikel lesen | |
| CG ONCOLOGY | 39,820 | -0,09 % | CG Oncology Inc.: CG Oncology Completes Enrollment in PIVOT-006 | - Rapid enrollment underscores high unmet need in intermediate-risk non-muscle invasive bladder cancer (NMIBC) -- One of the largest randomized phase 3 studies in this patient population will encompass... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,480 | -0,72 % | Recursion Pharmaceuticals: Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update | SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and... ► Artikel lesen | |
| ARVINAS | 9,610 | +3,61 % | Arvinas Inc.: Arvinas to Present Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders | ||
| IMMUNOME | 12,380 | +7,93 % | Where Immunome Stands With Analysts | ||
| JANUX THERAPEUTICS | 24,000 | +3,05 % | Janux Therapeutics: Günstige Gelegenheit | Janux Therapeutics hat mit seiner innovativen Plattformtechnologie im letzten Jahr das Interesse vieler Investoren geweckt - nicht zuletzt aufgrund von Übernahmegerüchten. Doch unabhängig von einem... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 10,310 | +0,29 % | ARS Pharma secures $250M loan to accelerate Neffy rollout | ||
| BIONTECH | 90,45 | +0,06 % | Achtung Übernahmen! BioTechs wie Evotec, PanGenomic Health, Pfizer und BioNTech im Fokus | Die BioTech-Branche ist in Aufruhr! Mit dem Wegfall von Blockbuster-Patenten drohen kräftige Umsatzrückgänge, die strategisch kompensiert werden müssen. Angetrieben durch wirtschaftlichen Druck und... ► Artikel lesen | |
| TAYSHA GENE THERAPIES | 4,770 | -2,25 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | DALLAS, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based... ► Artikel lesen | |
| EVOTEC | 6,744 | +2,00 % | Rheinmetall Aktie: Große Chance? - ABO Energy, Evotec, Funkwerk, MPC Capital und Redcare Pharmacy im Marktbericht Börse Frankfur | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 8,470 | +13,54 % | Aktien Europa: Leichte Gewinne zum Wochenauftakt | AMSTERDAM/LONDON/PARIS/ZÜRICH (dpa-AFX) - Europas wichtigste Aktienmärkte starten am Montag zunächst freundlich in die neue Woche. Allerdings blieb die Risikobereitschaft verhalten angesichts der bleiben... ► Artikel lesen | |
| LENZ THERAPEUTICS | 48,740 | +0,87 % | LENZ Therapeutics, Inc.: LENZ Therapeutics Announces Commercial Product Availability of VIZZ in the United States | VIZZ sample distribution initiated nationwide to Eye Care Professionals Commercial product shipments to be initiated in October to consumers with broad product availability by mid-Q4 2025 VIZZ is... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 65,18 | +10,89 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements | Record quarterly net product sales of $102.7 million achieved within two years of our XDEMVY® launch, an increase of 152% year over year Direct-To-Consumer campaign has activated new patients, expanded... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 47,010 | +6,41 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen |
SPAGO NANOMEDICAL AB gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,016 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SPAGO NANOMEDICAL AB finden Sie auf Wallstreet Online.